Has there been a shift in how the European courts approach preliminary injunctions?
par Dr Paul England et Christoph de Coster, LL.M. (UC Davis)
AI driven drug design
Unpacking the role of AI in bringing new drugs to market.
par Dr Paul England
1 de 6 Publications
The EU torpedoes itself in cross-border patent disputes
par Dr Paul England
Edison Open House Global Healthcare 2021 – key takeaways from our panel
par plusieurs auteurs
Will the UK government's COVID-19 dosing regime gamble pay off?
par Alison Dennis et Justyna Ostrowska
What the UK-EU Trade and Cooperation Agreement means for pharma and medical device companies
par Alison Dennis
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
par Alison Dennis et Dr Paul England
SPC for ezetimibe/simvastatin considered invalid in preliminary relief proceedings
Targeted treatments – Part 3: the power of orphan drug protection
par Dr Paul England
German Federal Court of Justice invalidates Truvada SPC
Targeted treatments – Part 1: Targeted treatments: patents for particular populations
par Dr Paul England
CJEU ruling to liberalise parallel import in Poland